이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

인슐린 저항성에 따른 인슐린 분비 조절을 위한 알파-베타 세포 간 상호작용의 역할 (UPGRADE)

2026년 9월 28일 업데이트: David D'Alessio, M.D.

건강과 질병에서의 알파 세포와 베타 세포 간의 상호작용

Glucagon secretion from α-cells has long been viewed as primarily a counterregulatory mechanism - e.g. an agent with a role to prevent blood sugar from decreasing to levels that compromise function. Our group, along with other researchers, have begun to identify a much more complex role for α-cells, raising questions about when and how glucagon may influence blood glucose levels. This proposal looks to detail proglucagon peptide secretion from α-cells and the impact this has on β-cell function and glucose tolerance, in preclinical studies of human islets and translational studies in human subjects. This protocol registration describes Aim 2 from this NIH grant which involves 2 study populations and separate protocols but addresses a common question. Aim 3 in the grant is focused on a separate hypothesis and will be conducted and published separately from Aim 2.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Subjects will undergo screening for medical history, medication usage, and blood work; those who qualify will be offered participation. Study participation will last approximately 4-8 weeks depending on the study protocol enrolled and appointment availability.

Aim 2A (Aim 1 of the protocol): Each participant will have two 5-hour hyperglycemic clamp procedures to test the effect of fasting glucagon-like peptide 1 (GLP-1) action before and after experimental insulin resistance. The effect of endogenous proglucagon peptides (glucagon and GLP-1) to stimulate insulin secretion will be determined by blockade of the GLP-1 receptor with the antagonist exendin-9 (Ex-9) during glucose infusions. Insulin secretion experiments will be repeated before and after induction of insulin resistance. To induce insulin resistance, subjects will take dexamethasone, a synthetic glucocorticoid that has been shown in published studies and in a pilot study by our group to reduce insulin sensitivity by ~30%.

Effective following a protocol revision in August 2026, participants in Aim 2A will also complete a third study visit that consists of two identical, sequential hyperglycemic clamps to evaluate time-of-day effects on insulin response independent of Ex-9. This protocol revision is a result of observations from the Aim 2A sub-study.

Aim 2A sub-study (Aim 1a of the protocol): Implemented in July 2026, a small subset of participants completed a single study visit to undergo two identical, sequential hyperglycemic clamps to examine potential time-of-day effects on glucose-stimulated insulin secretion.

Aim 2B (Aim 2 of the protocol): This study will recruit non-diabetic subjects with obesity. They will be studied on two occasions using a 4.5-hour procedure with a hyperglycemic clamp to measure insulin secretion, followed by a hyperinsulinemic, euglycemic clamp to measure insulin sensitivity. This procedure will be done 2 times, once with saline infused during hyperglycemia as a control, and once with exendin-9 given during hyperglycemia to determine the role of GLP-1 receptor action.

연구 유형

중재적

등록 (추정된)

30

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • North Carolina
      • Durham, North Carolina, 미국, 27705
        • 모병
        • Duke Center for Living
        • 연락하다:
        • 수석 연구원:
          • David D'Alessio, MD
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Aim 2A and 2A sub-study: Inclusion Criteria:

  • Age 18-45
  • Body Mass Index (BMI) < 27.0
  • Fasting plasma glucose of ≤ 95 mg/dL or HbA1c value ≤ 5.8% as measured at screening visit

Exclusion Criteria:

  • Active medical disease: e.g. active infectious, inflammatory, neurodegenerative or mental health disorders
  • Personal history of diabetes or pancreatitis
  • Personal history of cardiac, gastrointestinal, renal or liver disease
  • Immediate family history of diabetes
  • Renal insufficiency (eGFR < 60 mL/kg/min)
  • Anemia (hematocrit < 34%) as measured at screening visit
  • Pregnant females
  • Poor vein access
  • Consumption of daily medications that alter glucose metabolism of GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)
  • Apparent sensitivity to the study peptide as determined by the skin test

Aim 2B: Inclusion Criteria:

  • Age 35-60
  • Body Mass Index (BMI) ≥ 27.0
  • Fasting plasma glucose of < 126 mg/dL or HbA1c value < 6.5% as measured at screening visit

Exclusion Criteria:

  • Active medical disease: e.g. active infectious, inflammatory, neurodegenerative or mental health disorders
  • Personal history of diabetes or pancreatitis
  • Personal history of cardiac, gastrointestinal, renal or liver disease
  • Immediate family history of diabetes
  • Renal insufficiency (eGFR < 60 mL/kg/min)
  • AST and/or ALT levels > 3x the upper limit of the normal range
  • Anemia (hematocrit < 34%) as measured at screening visit
  • Pregnant females
  • Poor vein access
  • Consumption of daily medications that alter glucose metabolism of GI function (glucocorticoids, psychotropics, narcotics, metoclopramide)
  • Apparent sensitivity to the study peptide as determined by the skin test

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 기초 과학
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 2A [revised 8/2026]: Glucose-stimulated insulin secretion with and without GLP-1 receptor blockade

Aim 2A [revised AUG 2026]: Each subject will have a 5 hr experiment with sequential hyperglycemic clamps separated by a 90-minute washout. Plasma glucose will be increased with an intravenous (IV) infusion of 20% dextrose and maintained at ~140 mg/dL for 90 minutes. Following the washout, a second, identical hyperglycemic clamp will be performed. Subjects will receive an infuson of saline during the first clamp and receive exendin-9 (600 pmol/kg/min) during the second clamp. Intervention: The interventions here are the experimental hyperglycemia with and without exendin-9.

Subjects in Aim 2A will receive exendin-9 on two experimental days; Subjects in Aim 2B will receive exendin-9 on one of their two experimental days.

Dexamethasone 6 mg daily; administered for 7 days leading up to the second exendin-9 experiment in Aim 2A

Administered intravenously to maintain a stable blood glucose level of basal + 2.5 mM

Administered intravenously to maintain a stable blood glucose level of 6.0 mM

실험적: Aim 2A [revised 8/2026]: Sequential glucose-stimulated insulin secretion

Aim 2A [revised AUG 2026]: Each subject will have a 5 hr experiment with sequential hyperglycemic clamps separated by a 90-minute washout. Plasma glucose will be increased with an intravenous (IV) infusion of 20% dextrose and maintained at ~140 mg/dL for 90 minutes. Following the washout, a second, identical hyperglycemic clamp will be performed. Subjects will receive an infusion of saline during both clamps and the procedure will align with the temporal pattern applied during all procedures in Aim 2A. Experiment: The experiment in this arm is the examination of potential time of day effects on glucose-stimulated insulin secretion.

Administered intravenously to maintain a stable blood glucose level of basal + 2.5 mM

Administered intravenously to maintain a stable blood glucose level of 6.0 mM

실험적: 2A [discont'd 8/2026]: Glucose-stimulated insulin secretion with and without GLP-1 receptor blockade

Aim 2A [discontinued AUG 2026]: Each subject will have a 5 hr experiment with sequential hyperglycemic clamps separated by a 90-minute washout. Plasma glucose will be increased with an intravenous (IV) infusion of 20% dextrose and maintained stable at ~140 mg/dL for 90 minutes. Following the washout, a second, identical hyperglycemic clamp will be performed. Subjects will receive either saline or exendin-9 (600 pmol/kg/min) during the clamps; in 10 subjects the saline/clamp will be first and in 10 subjects the exendin-9/clamp will be first; this will be assigned in alternating order as individuals are enrolled. Intervention: The interventions here are the experimental hyperglycemia with and without exendin-9.

Subjects in Aim 2A will receive exendin-9 on two experimental days; Subjects in Aim 2B will receive exendin-9 on one of their two experimental days.

Administered intravenously to maintain a stable blood glucose level of basal + 2.5 mM

Administered intravenously to maintain a stable blood glucose level of 6.0 mM

실험적: 2A: Glucose-stimulated insulin secretion with/without GLP-1 receptor blockade and insulin resistance

Aim 2A: Subjects will be treated with 6 mg dexamethasone once daily for 7 days to induce insulin resistance before repeating the 5 hr glucose clamp study. The infusion of glucose with saline and exendin-9 will be performed identically to the first study. Intervention: The intervention in this arm is the induction of insulin resistance with dexamethasone treatment.

Subjects in Aim 2A will receive exendin-9 on two experimental days; Subjects in Aim 2B will receive exendin-9 on one of their two experimental days.

Administered intravenously to maintain a stable blood glucose level of basal + 2.5 mM

Administered intravenously to maintain a stable blood glucose level of 6.0 mM

실험적: 2B: Glucose-stimulated insulin secretion and insulin sensitivity

Aim 2B: Each subject will have a 4.5 hr experiment with a 90-minute hyperglycemic clamp at a level of 2.5 mM above fasting glucose followed by a 60-minute gradual reduction in glucose infusion that leads to a 90-minute hyperinsulinemic (80 units/meter2 Body Surface Area/minute), euglycemic clamp at a level of 6 mM.

Administered intravenously to maintain a stable blood glucose level of basal + 2.5 mM

Administered intravenously to maintain a stable blood glucose level of 6.0 mM

실험적: 2B: Glucose-stimulated insulin secretion with GLP-1 receptor blockade and insulin sensitivity

Aim 2B: Subjects will receive an infusion of exendin-9 (600 pmol/kg/min) or saline during the 90-minute hyperglycemic clamp period of the procedure. Subjects receiving exendin-9 during their first procedure will receive saline during their second procedure and vice versa; in 10 subjects the saline/clamp will be administered first and in 10 subjects the exendin-9/clamp will be administered first; this will be assigned in alternating order as individuals are enrolled. The hyperinsulinemic, euglycemic clamp during the second portion of the procedure will be conducted identically to the control arm.

Intervention: The intervention in this study is the administration of exendin-9 during experimental hyperglycemia.

Subjects in Aim 2A will receive exendin-9 on two experimental days; Subjects in Aim 2B will receive exendin-9 on one of their two experimental days.

Administered intravenously to maintain a stable blood glucose level of basal + 2.5 mM

Administered intravenously to maintain a stable blood glucose level of 6.0 mM

실험적: Aim 2A sub-study [discont'd 8/2026]: Sequential glucose-stimulated insulin secretion

Aim 2A control sub-study [discontinued AUG 2026]: Each subject will have a 5 hr experiment with sequential hyperglycemic clamps separated by a 90-minute washout. Plasma glucose will be increased with an intravenous (IV) infusion of 20% dextrose and maintained at ~140 mg/dL for 90 minutes. Following the washout, a second, identical hyperglycemic clamp will be performed. Subjects will receive an infusion of saline during both clamps and the procedure will align with the temporal pattern applied during all procedures in Aim 2A. Experiment: The experiment in this arm is the examination of potential time of day effects on glucose-stimulated insulin secretion.

Administered intravenously to maintain a stable blood glucose level of basal + 2.5 mM

Administered intravenously to maintain a stable blood glucose level of 6.0 mM

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Insulin secretion with and without exendin-9: Aims 2A and 2B
기간: 4-8 weeks

Insulin secretion rates derived from deconvolution of C-peptide concentrations will be the primary outcome for insulin secretion. This measure will be compared within subjects in Aim 2A with the difference between the saline and exendin-9 clamps on each day used as the measure of fasting GLP-1 receptor mediated insulin secretion. Comparison of GLP-1 receptor mediated insulin secretion between the placebo and dexamethasone studies will be used to determine the effect of insulin resistance. Comparison of insulin secretion during the two sequential saline clamps in Aim 2A (revised 8/2026) and Aim 2A sub-study will be used to determine a time-of-day effect of subsequent glucose clamps.

Insulin secretion rates will also be compared within subjects in Aim 2B. Here the two different study days, one with saline and one with exendin-9 will be used.

4-8 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
Insulin sensitivity: Aim 2B
기간: Insulin sensitivity will be measured in subjects participating in Aim 2B during the hyperinsulinemic clamp in each of the two days of study. The two experiments will be completed in a 4-6 week period.

Insulin sensitivity will be measured directly in subjects in Aim 2B during the hyperinsulinemic, euglycemic clamp. The glucose infusion rate necessary to maintain blood glucose at 6 mM divided by steady-state plasma insulin will be used as the index of insulin sensitivity.

Insulin sensitivity will be measured in subjects participating in Aim 2B during the hyperinsulinemic clamp in each of the two days of study. The two experiments will be completed in a 4-6 week period.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: David D'Alessio, MD, Duke University

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 12월 30일

기본 완료 (추정된)

2027년 12월 1일

연구 완료 (추정된)

2027년 12월 1일

연구 등록 날짜

최초 제출

2025년 10월 29일

QC 기준을 충족하는 최초 제출

2025년 11월 2일

처음 게시됨 (실제)

2025년 11월 4일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 28일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • Pro00116631
  • R01DK142423 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .